Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
To the Editor: Dr Rubin and colleagues suggested
that α-methylacyl coenzyme A racemase (AMACR) may be a tissue biomarker
for prostate cancer.1 We agree that AMACR
is a promising diagnostic marker for prostate cancer and recently reported
that AMACR has high sensitivity for the detection of prostate cancer on needle
biopsy.2 However, it is important to recognize
the limitations of this marker. In our study of atypical adenomatous hyperplasia
of the prostate, a benign condition that mimics prostate cancer, AMACR immunoreactivity
was found in a small subset of cases (17.5%).3
Therefore, caution should be exercised in interpretation of AMACR immunostaining.
Jiang Z, Woda BA, Yang XJ. α-Methylacyl Coenzyme A Racemase as a Marker for Prostate Cancer. JAMA. 2002;287(23):3080-3081. doi:10.1001/jama.287.23.3077